Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutamate-rich protein 4 (ERICH4)
- Target
- ERICH4
- Molecular classification
- Other (Protein of unknown function; contains domain of unknown function DUF4530[1][4]), Intracellular protein (not a membrane protein, no transmembrane domains[1])
01
Overview
Glutamate-rich protein 4 (ERICH4) is a small, highly conserved intracellular protein with approximately 130 amino acids and an isoelectric point of 4.0[1]. It contains a domain of unknown function (DUF4530), is highly enriched for glutamate residues (17.7%), and is mainly expressed in human kidney, terminal ileum, and duodenum[1][6]. In silico analyses and limited experimental data suggest its possible involvement in immune responses and lipid metabolism, but knockout studies in mice indicate it does not play a discernible role in intestinal lipid absorption or chylomicron metabolism[2]. There are no established roles in signaling, cell regulation, or disease, nor are there known drugs or biomarkers associated with ERICH4. The gene is also known as C19orf69 or LOC100170765. Subcellular localization is predicted to be cytoplasmic and intracellular, with no transmembrane or secretory domains[1].
- Other names
- ERICH4Glutamate-rich protein 4C19orf69LOC100170765glutamate-rich protein 4 isoform X1
02
Mechanism of action
None (No known mechanism for drug action targeting ERICH4; no confirmed pharmacological relevance)
03
Biological functions
Other (proposed, not demonstrated: immune inflammatory response[1])Possible involvement, but unproven: intestinal lipid metabolism[2]No established biological function with evidence
04
Disease associations
Other (speculative links to plasma lipids, but not confirmed; no direct disease association with cancer, neurodegeneration, etc.[2])No validated disease association
05
Safety considerations
None (No known safety concerns or therapeutic challenges; ERICH4 is not a drug target[2][6])
06
Interacting drugs
None (No drugs are known to interact with or modulate ERICH4[3])
07
Biomarkers
None (Not in current clinical use for patient selection, monitoring, or as a biomarker for any disease[3][6])
Beyond the preview
Go deeper on Glutamate-rich protein 4 (ERICH4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glutamate-rich protein 4 (ERICH4).